Advertisement

Topics

Search Results for "Tingkatan Satu Sejarah Nota"

09:22 EST 28th February 2017 | BioPortfolio

Matching Channels

None

Matching News

New moth in Europe: A southern hemisphere species now resident in Portugal

(Pensoft Publishers) As travelling in the 21st century is easier than ever, so is for species to make their way to new areas, sometimes increasing their distributional range, or even establishing whol...

Los Angeles Weight Loss Specialist Dr. Michael Feiz to Appear on “Mama June: From Not to Hot”

Los Angeles, CA (PRWEB) February 23, 2017 Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will be appearing on the...

ValiRx boosts worldwide patent protection for VAL201

ValiRx Plc (LON:VAL) shares rose as it strengthened its worldwide patent protection for lead drug VAL 201 - having been granted a patent by the European office. It means the biotech now has patent p...

ValiRx's recent data well received

Recent presentations from life sciences firm ValiRx Plc (LON:VAL) have been warmly received, the group said in an update. The company has two drugs in clinical trials, VAL 201 for prostate cancer, a...

ValiRx prostate cancer drug delivers eye-catching early results

ValiRx Plc (LON:VAL) is extending its early stage trial of a prostate cancer drug after discovering the treatment is appears to working at lower doses than predicted. “[We are] entering a very exc...

ValiRx receives new patents in Japan and US for lead compounds

Cancer-focused biotech ValiRx Plc (LON:VAL) says its technology has been further endorsed with the award of new patents in Japan and the US. The patents relate to the firm's compounds VAL201 and VAL...

Ibrutinib (IMBRUVICA®) Supplemental New Drug Application Submitted to the U.S. Food and Drug Administration (FDA) for Marginal Zone Lymphoma (MZL)

RARITAN, N.J., Sept. 26, 2016 /PRNewswire/ -- Janssen Research & Development, LLC announced today that a supplemental New Drug Application (sNDA) for ibrutinib (IMBRUVICA®) has been subm...

New Ibrutinib (IMBRUVICA®) Phase 2 Data Demonstrate Promise in Relapsed/Refractory Marginal Zone Lymphoma (MZL), a Rare, Incurable Type of Non-Hodgkin's Lymphoma

SAN DIEGO and RARITAN, N.J., Dec. 5, 2016 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced results from a Phase 2 study demonstrating a 48% overall respon...

Matching PubMed Articles

Impact of dianionic and dicationic linkers on tumor uptake and biodistribution of (64) CuCu/NOTA peptide-based GRPR antagonists.

In this study we investigated for the first time the influence of 2-aminoethyl-piperazine-1-carboxylic acid (APCA) and amino-hexanedioic-1-acid (AHDA) on tumor uptake and elimination kinetics of [(64)...

Evaluation of a Flexible NOTA-RGD Kit Solution Using Gallium-68 from Different (68)Ge/(68)Ga-Generators: Pharmacokinetics and Biodistribution in Nonhuman Primates and Demonstration of Solitary Pulmonary Nodule Imaging in Humans.

Radiopharmaceuticals containing the motive tripeptide arginyl-glycyl-asparatic acid (RGD) are known to target ανβ3 integrins during tumor angiogenesis. A more generic kit radiolabeling procedure ac...

Targeting phosphatidylserine with a 64Cu-labeled peptide for molecular imaging of apoptosis.

Molecular imaging of programmed cell death (apoptosis) in vivo is an innovative strategy for early assessment of treatment response and treatment efficacy in cancer patients. Externalization of phosph...

Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI.

We performed pretreatment angiogenesis imaging (Ga-NOTA-arginyl-glycyl-aspartic acid [RGD] PET/CT) to compare its prognostic value to dynamic contrast-enhanced (DCE) MRI in breast cancer patients.

Miscommunicating NOTA can be Costly to Living Donors.

Misconceptions about if and how living donors may receive financial support appear to be widespread. These misconceptions may be perpetuated by unclear or incomplete language in informed consent docum...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement